Clinical trials: Human Papillomavirus Vaccines
Human Papillomavirus
Study of Gardasil in Mid-Adult Males (MAM)
The purpose of this study is to test the effectiveness of the research study vaccine, Gardasil, in men ages 27-45 who have completed 4 years of observation in The Human Papillomavirus [HPV] infection in men (HIM) Study.
- Trial name
- NCT01432574
- Testing
- Gardasil
- Where
- 2 sites in United States, Mexico
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cervical Cancer, Condylomata Acuminata
Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)
This study is to evaluate an investigational vaccine with the following objectives: (1) To demonstrate prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection…
- Trial name
- NCT00365443
- Testing
- V502
- Volunteers
- healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9vHPV vaccine in men 20 to 45 years of age.
- Trial name
- NCT04199689
- Testing
- 9vHPV Vaccine
- Where
- 103 sites in United States, Belgium and 14 more
- Volunteers
- 6,033 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV - Anogenital Human Papilloma Virus Infection, HIV Infections
Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study)
Phase IV prospective study measuring the immunogenicity (neutralizing antibody titles against each HPV vaccine genotype) of the 9-valent vaccine against HPV (Gardasil9®Merck) in HIV-positive women aged 15-40 years with fully…
- Trial name
- Papillon (NCT03391921)
- Testing
- Vaccine
- Where
- Belgium
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Cervical Carcinoma, Vaginal Carcinoma
HPV Vaccine, Imiquimod, and Metformin Combination Trial
The goal of this clinical trial is to explore whether additional treatments can help strengthen the participant's immune system to fight cancer caused by the Human Papillomavirus (HPV), a virus spread through intimate…
- Conditions
- Cervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma
- Trial name
- HPV-VIM (NCT06686043)
- Testing
- HPV vaccine, Imiquimod, and metformin combination therapy
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Baylor College of Medicine
HPV-Associated Cancers
This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers
This is a Phase 1/1b open-label dose escalation trial of Ad/MG1-E6E7 and sequential treatment with atezolizumab in patients with HPV associated cancers. This study will consist of two arms.
- Trial name
- Kingfisher (NCT03618953)
- Testing
- Ad-E6E7, MG1-E6E7, Atezolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Turnstone Biologics, Corp.
Vaccines, Meningococcal Vaccines
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17
This is a clinical study to assess the safety, tolerance and immunogenic response to Gardasil (human papilloma virus (HPV)) and rLP2086 vaccine.
- Trial name
- NCT01461993
- Testing
- rLP2086 and Gardasil, rLP2086, Gardasil
- Where
- 87 sites in United States
- Volunteers
- 2,499 people, healthy volunteers welcome
- Sponsor
- Pfizer
Human Papillomavirus, Uterine Cervical Neoplasms
An HPV Vaccine Provider Intervention in Safety Net Clinics
The purpose of this study is to develop, deliver and evaluate a provider intervention for mothers and their children to encourage receipt of the human papillomavirus (HPV) vaccine in the children and appropriate cervical cancer…
- Trial name
- NCT02808832
- Testing
- Educational materials
- Where
- United States
- Volunteers
- 806 people, healthy volunteers welcome
- Sponsor
- Meharry Medical College
Infections, Papillomavirus
A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females
A phase I, open label, single-centre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV -16/18 L1 VLP AS04 vaccine (GSK 580299, Cervarix TM), administered intramuscularly according to a 0, 1…
- Trial name
- NCT00549900
- Testing
- GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV-16 +ve Oropharyngeal Carcinoma
Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer
It is the investigators intention to investigate whether a specially designed vaccine, based on a genetically modified strain of the bacterium Listeria monocytogenes and called ADXS11-001 is safe to use and is able to boost the…
- Trial name
- REALISTIC: (NCT01598792)
- Testing
- ADXS11-001
- Where
- 4 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- University of Liverpool
Papillomavirus Type 16/18 Infection, Cervical Intraepithelial Neoplasia
Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women
The study will be extended for subjects who received all three doses of vaccine in Finland, Denmark and Estonia to determine long-term safety and immunogenicity of the HPV-16/18 vaccine.
- Trial name
- NCT00337818
- Testing
- Cervarix™
- Where
- Estonia
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papilloma Virus
Impact of Standing Orders Optimization
This trial will look at the impact of optimizing human papillomavirus (HPV) vaccine standing orders. The research team will work with primary care clinics. Some clinics will receive communication training.
- Trial name
- NCT05742386
- Testing
- Communication training, Communication training enhanced with standing orders optimization
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Human Papillomavirus Vaccines
Community Pharmacists Vaccinate Against Cancer
Latino and African American populations have a higher rate of human papillomavirus (HPV) vaccine initiation; however, they have a significantly less likelihood of completing the vaccine series.
- Trial name
- CPVAC (NCT04072159)
- Testing
- Community Pharmacists Vaccinating Against Cancer
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Arizona State University
Human Papillomavirus Infection
Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers
The primary objectives of this study are to determine the acceptance and potential for the effective use of HPV vaccine in the standard and a modified schedule in female sex workers.
- Trial name
- Girasol (NCT00925288)
- Testing
- Gardasil
- Where
- Peru
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Infections, Papillomavirus
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current study is designed to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine…
- Trial name
- NCT00586339
- Testing
- Cervarix
- Where
- South Africa
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papilloma Virus, Vaccine-Preventable Diseases
Hashtag HPV: HPV Vaccine Twitter Education Program
Parents use social media as an important parenting tool and source for health information. Using social media data to examine public opinion has had an early impact in public health and in cancer control and prevention efforts…
- Trial name
- NCT05204030
- Testing
- HPV Twitter Education Program - Narrative, HPV Twitter Education Program - Non-Narrative
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Arkansas, Fayetteville
Dengue Fever
Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years
The purpose of the study is to demonstrate the non-inferiority (NI) of the immune response to 2 doses of 9vHPV vaccine, 1 co-administered with TDV, compared with 2 doses of 9vHPV vaccine administered alone.
- Trial name
- NCT04313244
- Testing
- 9vHPV Vaccine, Dengue Tetravalent Vaccine (TDV)
- Where
- 4 sites in Thailand
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- Takeda
Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma
Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study
This phase IV trial investigates whether one dose of a human papillomavirus vaccine works as well as two doses in preventing human papillomavirus (HPV) infection. Certain types of HPV cause almost all cases of cervical cancer.
- Trial name
- ESCUDDO (NCT03180034)
- Testing
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Questionnaire Administration, Recombinant Human Papillomavirus Bivalent Vaccine
- Where
- Costa Rica
- Volunteers
- 27,945 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Vaccine Therapy in Treating Patients With Recurrent or Persistent Cervical Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients with recurrent or persistent cervical cancer that…
- Trial name
- NCT00003977
- Testing
- human papillomavirus 16 E7 peptide, in vitro-treated peripheral blood stem cell transplantation
- Where
- United States
- Sponsor
- Steward St. Elizabeth's Medical Center of Boston, Inc.
Human Papillomavirus Infections
GARDASIL™ Vaccine Impact in Population Study (V501-033)
This study will assess the impact of GARDASIL™ human papillomavirus (HPV) vaccine in the general female population by utilizing nationwide registry databases in the participating Nordic countries.
- Trial name
- VIP (NCT01077856)
- Volunteers
- 54,516 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC